Stifel Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Stifel analyst Laura Prendergast initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $23.
Stifel analyst Laura Prendergast initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $23.